Since then, anti-vascular endothelial growth factor (VEGF) therapy has monopolized the treatment of nAMD. In this review, we present and comment on the response to both complement and ...
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results